Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermapharm Holding SECHIX:DMPD 73 Future 3-5Y EPS without NRI Growth Rate is 10.58 as of Sep. 15, 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 73/100 and a GF Value™ of €35.46 (Fairly Valued). The stock has 5 warning signs investors should review. Among 230 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 74.35% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Dermapharm Holding SE's Future 3-5Y EPS without NRI Growth Rate is 10.58.
Dermapharm Holding SE (CHIX:DMPd) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Dermapharm Holding SE Future 3-5Y EPS without NRI Growth Rate Related Terms
CHIX:DMPD vs ZTS, UTHR, VTRS: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 10.58 mean?
Dermapharm Holding SE (CHIX:DMPD) has a Future 3-5Y EPS without NRI Growth Rate of 10.58 as of Sep. 15, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Dermapharm Holding SE and its competitors. According to the industry distribution chart, Dermapharm Holding SE ranks #171 out of 230 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is Dermapharm Holding SE's Future 3-5Y EPS without NRI Growth Rate too high?
Dermapharm Holding SE's current Future 3-5Y EPS without NRI Growth Rate is 10.58. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 17.14. Dermapharm Holding SE's value of 10.58 is 38.3% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #171 out of 230 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Future 3-5Y EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #171 out of 230 companies for Future 3-5Y EPS without NRI Growth Rate. This places Dermapharm Holding SE in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.14. Dermapharm Holding SE's value of 10.58 is 38.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 17.14, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Future 3-5Y EPS without NRI Growth Rate of 10.58 is 38.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Future 3-5Y EPS without NRI Growth Rate is 10.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (CHIX:DMPD) is currently considered Fairly Valued. The stock's GF Value™ is €35.46, compared to a current price of €38.63 — trading 8.9% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 10.58 and 38.3% below the Drug Manufacturers industry median of 17.14. Dermapharm Holding SE's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Future 3-5Y EPS without NRI Growth Rate is 10.58 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €38.63 is trading 8.9% above its estimated GF Value™ of €35.46.
GuruFocus considers Dermapharm Holding SE to be Fairly Valued.
Key valuation signals for CHIX:DMPD:
Future 3-5Y EPS without NRI Growth Rate: 10.58
GF Value™: €35.46 vs. price of €38.63 (8.9% above fair value)
Industry Position: 38.3% below the Drug Manufacturers median (#171 of 230)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
73GF Score
Get the complete analysis for CHIX:DMPD
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
